The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

DrugBank

JULY 18, 2024

Adjuvants are substances added to vaccines to enhance the immune response. They work by decreasing the solubility of the vaccine, which sustains the release of the drug and prolongs the immune response. Even after a vaccine is approved and distributed, the pharmaceutical industry's responsibility does not end.

Vaccine 79

Vaccine Immune Response Clinical Trials Disease 79

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) In addition, the T-cell responses are especially strong and stable over time, which is also potentially important for activity against these variants.”.

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Immune responses were similar across the age groups studied, including older adults.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. The interim findings are from phase 3 trials in the United Kingdom and Brazil that included more than 11,600 participants. Further Support and Information on COVID-19. TUESDAY, Dec. 8 in The Lancet. Source link.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 — Children should be included in clinical trials for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine at the earliest stages, according to a letter from the president of the American Academy of Pediatrics (AAP), on behalf of more than 67,000 pediatricians and pediatric medical and surgical subspecialists.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

The Pharma Data

NOVEMBER 12, 2020

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. No new safety signal for Calquence was observed in the trials. No new safety signal for Calquence was observed in the trials.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial. About previously-published preclinical results.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners.

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. The trial will include equal numbers of adults 18 to 59 years and those 60 years and above. Results of the Phase 2 trial will inform the Phase 3 protocol. About the Phase 2 study.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 is being evaluated in an ongoing Phase 3 trial in the U.K. and Australia. About Matrix-M.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant.

Vaccine 52

Vaccine Immune Response Virus RNA 52

NIH Director's Blog: Drug Development

DECEMBER 15, 2020

What’s been missing is a one-stop online information portal that pulls together the most current information for people of all groups, races, ethnicities, and backgrounds who want to get involved in fighting the pandemic. Why get involved in a clinical trial now if vaccines will be widely distributed in the future?

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Premier Consulting Blog

APRIL 18, 2024

This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapy product. Prior to clinical trials, the focus is typically on evaluating safety. Can you identify a safe AND efficacious clinical dose? Author: Madelyn Huang , PhD, DABT, Toxicologist

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

The Pharma Data

JANUARY 5, 2021

5, 2021 — Stem cells derived from a baby’s umbilical cord can help save the lives of the sickest COVID-19 patients, results from a small new clinical trial suggest. TUESDAY, Jan. Half were randomly chosen to receive two separate IV infusions of 100 million stem cells, while the others received a placebo IV.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

JANUARY 22, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. 24, 2020 ). Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.”.

Immune Response 52

Immune Response Clinical Trials Hospitals Trials 52

The Pharma Data

OCTOBER 9, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

Drug Target Review

OCTOBER 17, 2024

While its involvement in the do-not-eat-me signal from cancer has inspired therapeutic development of this pathway for oncology, the function of the innate immune checkpoint we identified in 2009 1 extends to both innate and adaptive immune responses. Biomarkers are the holy grail of clinical trials. References Chen GY.,

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

The Pharma Data

NOVEMBER 14, 2020

In addition to the single-dose regimen ENSEMBLE study, Janssen has now initiated the two-dose regimen ENSEMBLE 2 trial. The ENSEMBLE and ENSEMBLE 2 trials will run in parallel. The interim analysis showed that a single dose of the COVID-19 vaccine candidate induced a robust immune response and was generally well-tolerated.

Clinical Trials 40

Clinical Trials Vaccine Trials Pharmaceutical Companies 40

The Pharma Data

MARCH 8, 2021

The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy 4. Two Phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings 2,3.

Immune Response 52

Immune Response Clinical Trials Trials Treatment 52

The Pharma Data

JANUARY 12, 2021

Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It It is a new immune checkpoint that is expressed on three different immune cells: Macrophages, [Natural Killer] NK cells, and T cells. [It]

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

Codon

SEPTEMBER 29, 2024

The average pass rate of phase I trials went up by 5 percent. Their pipelines were bursting with promising candidates, and their success rates in clinical trials were astronomical compared to the industry standard of just a few years back. A flurry of new, promising therapeutic targets arose. It started small.

Engineering 138

Engineering Virus DNA Therapies 138

The Pharma Data

MARCH 9, 2021

The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy 4. Two Phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings 2,3.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

OCTOBER 6, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

NOVEMBER 9, 2020

Novavax expects to begin its pivotal Phase 3 clinical trial in the United States and Mexico by the end of November. Data from the event-driven trial could support global authorization and approval, including in the U.S. and globally.”. About NVX-CoV2373. and Australia.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

JANUARY 3, 2021

reports that Scentech-Medical received approval from the Shamir Medical Center ( Asaf Harofe ) Review Board ( Helsinki committee) for a new clinical trial. Moreover, such a test has the potential to indicate the immune system’s response to various types of vaccines. View original content: [link].

Clinical Trials 40

Clinical Trials Vaccine Trials Immune Response 40

The Pharma Data

JULY 8, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Pharmaceutical Companies Disease 52

The Pharma Data

NOVEMBER 30, 2020

Two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored by Novavax are fully enrolled, and more than 20,000 participants have been dosed to-date. In alignment with Novavax’ commitment to transparency, Phase 3 clinical trial protocols are posted to the company’s website at Novavax.com/resources upon finalization.

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 11, 2020

” Coronaviruses are notorious for prompting a flawed and incomplete immune response in humans, infectious disease experts say. “In those that have recovered, the vaccine will boost natural immunity and it will be more effective at preventing disease,” he said. Further Support and Information on COVID-19.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

NOVEMBER 18, 2020

. “Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833.” Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52